We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Science Group Plc | LSE:SAG | London | Ordinary Share | GB00B39GTJ17 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 415.00 | 410.00 | 420.00 | 415.00 | 415.00 | 415.00 | 10,950 | 07:43:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Consulting Svcs,nec | 98.82M | 10.56M | 0.2322 | 17.87 | 188.65M |
Date | Subject | Author | Discuss |
---|---|---|---|
24/5/2011 16:48 | even so it is cheap. mkt cap £32m, £9.5m of cash and a property worth £14m. That's £7.5m for the underlying business. Which ex the property income will probably do £2.2m of pre tax this year, so 3.4x current year profits. the cash balance will continue to rise unless they do a deal, and there is scope to do something with the property. So upside from; 1) a re-rating, 2) growing cash, 3) a property deal (re-development?) 4) a deal 5) a dividend Don't forget FD buying not that long ago at 67pish, and they are getting permission back to buy shares. NAV is 55p. I think this is pretty solid with some upside. | oregano | |
16/5/2011 17:53 | ...and has limited visibility. Otherwise it would be very tempting. | wjccghcc | |
16/5/2011 09:57 | nice statement today - materially ahead should mean 15-20% or better imo. Shame it's so hideously illiquid at times. CR | cockneyrebel | |
16/5/2011 09:19 | Thanks for that. | truffle | |
16/5/2011 08:51 | Neither now with the rise to 81p :-) 41,723m shares x 81p = £33.79m market cap. ic2.... | interceptor2 | |
16/5/2011 08:18 | My screen says a market cap. of £17.7 million, not £31 million. Which is correct? | truffle | |
16/5/2011 08:14 | Luvverly jubberly | stegrego | |
16/5/2011 07:45 | Materially ahead and net cash £9.5m, against a market cap of £31.0m. And the cash keeps on increasing. I also like the fact they are taking time over selecting an acquisition and say they will remain prudent in the process. When SAG find a suitable acquisition, I bet it will be very earnings enhancing. ic2..... | interceptor2 | |
16/5/2011 07:23 | Hopefully get an uplift today. | chester | |
07/4/2011 20:50 | Added a few more today, had to pay a penny premium for 5k and they only dealt 2k initially and still at a premium. Was quoted 80p for 10k so obviously short of stock at these levels. | matt123d | |
31/3/2011 08:51 | Getting closer. | chester | |
29/3/2011 08:29 | Breakout is a close above 74.5p. | chester | |
28/3/2011 19:35 | yep, posted that one on my thread today intterceptor2 - nice show of confidence. CR | cockneyrebel | |
28/3/2011 19:25 | Director dealing Sagentia Group plc (AIM: SAG, the "Company") was informed today that on 25 March 2011 a trust in which Brent Hudson, Chief Executive Officer, has a beneficial interest, acquired 29,411 ordinary shares of 1p each in the Company at a price of 68 pence per share. Following this purchase, Brent Hudson is interested in 94,411 ordinary shares, representing 0.2 per cent. of the issued share capital of the Company. In addition, Brent Hudson is interested in 1,500,000 options over ordinary shares in the Company. I think this is significant news, to increase direct holding at the market price. I know his options dwarf his holdings, but he must be feeling confident of current trading. ic2....... | interceptor2 | |
17/3/2011 12:35 | Photocure, Sagentia to test drug-device for HPV, cervical pre-cancer PBR Staff Writer Published 16 March 2011 Norwegian specialty pharmaceutical company Photocure and Sagentia have received US Food and Drug Administration (FDA) approval to initiate Phase II clinical trial on Cevira, a drug-device being developed to treat Human Papilloma Virus (HPV) infection and precursors of cervical cancer. The trial will begin in multiple centres across the US and Europe during the spring this year. Cevira delivers a light-activated treatment known as photodynamic therapy to destroy tissue infections caused by HPV and treat precancerous lesions on the cervix without affecting healthy tissue. Cevira contains a LED light source in combination with a drug that initiates a photochemical reaction in exposed tissue. The device can be administered by a trained gynaecologist or colposcopist and is left in the cervix up to one-day, during which time the patient can leave the hospital and continue with her daily activities, allowing the patient remove and dispose the device herself. The trials will evaluate the photodynamic therapy in patients with cervical pre-cancer as an alternative to laser therapy, surgical conisation, LEEP excision or cryotherapy and investigate treatment suitability in patients with mild cervical abnormalities. | orange1 | |
03/3/2011 15:15 | Another 4.0m sold today @ 70p without moving the price, suggests an agreed transaction between institutional investors imo. There must be a RNS soon. Should be interesting. Regards.......... | interceptor2 | |
01/3/2011 17:01 | Thats about 8% of the shares so we should see a RNS soon. Thanks for highlighting the £9.0m of tax credits left in an earlier post cr. Saves me looking through the statements. Worth remembering they will have to use 41.723m shares in the future to calculate the EPS against 33.011. But of course if they commence on share buybacks this year, it should reduce this figure. Regards........ | interceptor2 | |
01/3/2011 16:48 | woah, 3.6m traded, the highest volume day ever. I had heard Standard Life were an overhang, hopefully this is them out the way. onwards and upwards. | oregano | |
01/3/2011 15:09 | i don't think they have permission until agreed at the AGM. post results meetings going down well i imagine. i have been topping up and there is not much stock around. | oregano | |
01/3/2011 14:58 | Look at those trades - share buy backs? CR | cockneyrebel | |
01/3/2011 14:42 | Looking much firmer - don;t understand traders selling yesterday. CR | cockneyrebel | |
01/3/2011 11:14 | Buyers grabbing that mad dip here. Some might think this is an exceptional year but I doubt it - the co has always guided cautiously under Ratcliffe and will do so still imo - then they hit you with an 'ahead' statement. Buy backs would be good. No tax to pay for ages too imo CR | cockneyrebel | |
28/2/2011 10:50 | I see they say they might start doing buybacks. Maybe people see this as an exceptional year rather than the norm? | stegrego |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions